Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lucid-21-302 · 2 trials · 2 indications
Safety Outcome Measure
Safety Outcome Measure
Safety Outcome Measure
Safety blood test measured by a laboratory using a reference range
Safety blood test measured by a laboratory using a reference range
Safety blood test measured by a laboratory using a reference range
Safety urine test measured by a laboratory using a reference range
Safety Outcome Measure, clinical exam performed by a licensed physician
Safety Outcome Measure, measured in mmHg
Safety Outcome Measure, measured in mmHg
Safety Outcome Measure, measured in beats per minute
Safety Outcome Measure, measured in breaths per minute
Safety Outcome Measure, measured in degrees Celcius
Safety Outcome Measure, measured using a standard ECG machine
Safety Outcome Measure, PHQ-9 is a depression scale with scores ranging from 0 to 27 with higher scores indicating more depressive symptoms
Safety Outcome Measure, GAD7 is an anxiety scale with scores ranging from 0 to 21 with higher scores indicating more anxiety symptoms
Safety Outcome Measure, C-SSRS is an assessment tool that measures suicidal ideation and behavior. It consists of ten yes or no questions with yes answers indicating more thoughts of suicidality.
Safety Outcome Measure, neurological exam performed by a licensed physician
Incidence and severity of adverse events (AEs), laboratory, ECG, physical exam, neurological exam and vital sign changes
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
| Arm | Type | Description |
|---|---|---|
| Lucid-21-302 | EXPERIMENTAL | Multiple ascending dose cohorts |
| Placebo | PLACEBO_COMPARATOR | Multiple ascending dose cohorts |
| Name | Type | Description |
|---|---|---|
| Lucid-21-302 | DRUG | Capsule containing a small molecule inhibitor of hypercitrullination |
| Placebo | DRUG | Capsule containing only Silicified Microcrystalline Cellulose |
Inclusion Criteria: 1. Male or female, aged ≥18 and ≤60 years (inclusive), with BMI \>18.0 and \<32.0 kg/m2 and body weight ≥50.0 kg. Social smokers consuming less than 10 cigarettes per week, with a negative cotinine test at screening and Day -1 will be allowed. 2. Participant is judged by the Inv...
Lucid-21-302 is an investigational small molecule drug developed by Quantum Biopharma Ltd. It has been studied in Phase 1 clinical trials involving healthy adult volunteers. The specific medical conditions it is intended to treat have not been publicly disclosed.
Lucid-21-302 is being developed by Quantum Biopharma Ltd., which trades under the ticker QNTM. The company has sponsored Phase 1 clinical trials of the drug in Australia and Canada.
Lucid-21-302 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The drug has not been approved by the FDA or any other regulatory agency.
Lucid-21-302 has been evaluated in two completed Phase 1 trials. NCT05821387 studied safety, tolerability, pharmacokinetics, and food effects in 40 healthy volunteers in Canada. NCT06595706 evaluated safety and pharmacokinetics of multiple ascending doses in 16 healthy participants in Australia.
Yes, the Phase 1 trials of Lucid-21-302 were randomized, double-blind, and placebo-controlled. The studies enrolled a total of 56 healthy adult participants across sites in Australia and Canada.